Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study

New data package reveals improvements in multiple categories for TPST-1120 combined with atezolizumab + bevacizumab versus standard of care atezol...

Related Keywords

United States ,California ,Brisbane ,Queensland ,Australia ,Roche Imbrave ,Roche ,Sylvia Wheeler ,Stephen Brady ,Aljanae Reynolds ,Office For Health Improvement Disparities ,Securities Exchange ,World Health Organization ,Tempest Therapeutics Inc ,Exchange Commission On ,Nasdaq ,Randomized Clinical ,East Asia ,Securities Exchange Act ,Securities Act ,Tempest Therapeutics ,Exchange Commission ,Tempest Therapeutic ,Clinical Oncology ,Liver Cancer ,Reviews Disease ,Health Improvement ,